Soleno Therapeutics, Inc. Series A Warrant
SLNOW
SLNOW was delisted on the 8th of November, 2019.
3 hedge funds and large institutions have $205K invested in Soleno Therapeutics, Inc. Series A Warrant in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
754% more capital invested
Capital invested by funds: $24K → $205K (+$181K)
50% more funds holding
Funds holding: 2 → 3 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$64.8K |
Top Sellers
SLNOW Hedge Fund Activity: Q4 2018 in Review
3 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics, Inc. Series A Warrant (SLNOW) for Q4 2018, worth a combined $205K — up 754% from $24K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SLNOW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $64.8K.
- 3 institutional investors held Soleno Therapeutics, Inc. Series A Warrant (SLNOW) as of Q4 2018, up from 2 in Q3 2018.
- Funds reported $205K of Soleno Therapeutics, Inc. Series A Warrant stock for Q4 2018, up 754% quarter-over-quarter.
- 1 fund opened new Soleno Therapeutics, Inc. Series A Warrant positions in Q4 2018 and 0 closed out, a net change of +1 holder.
- The largest Soleno Therapeutics, Inc. Series A Warrant buyer in Q4 2018 was 683 Capital Management, an estimated $64.8K added.
Based on aggregated 13F filings for Q4 2018.